Title: Muscle weakness<br/>Author: Kathy Prybys<br/><a href='http://umem.org/profiles/faculty/121/'>[Click to email author]</a><hr/><p>
<span font-size:="" new="" style="font-family: " times=""> A 68 year old male presents to the ED complaining of weakness to his legs. He states today his yard chores took him over 2 hours to complete instead of the usual 15-20 minutes due need to take frequent breaks for rest due to leg pain. He denied any chest pain or shortness of breath. </span>Past medical history included hypercholesteremia, HTN, and CAD. He is taking aspirin and recently started on rosuvastatin.</p>
<p>
His physical exam was unremarkable.</p>
<p>
Results showed normal EKG and CBC. Bun was 70, Creatinine was 3.4, and CPK of 1025.</p>
<p>
This patient has statin induced rhabdomyolysis and acute renal failure.</p>
<p>
<u><strong>Take Home Points:</strong></u></p>
<ul>
<li>
Rhabdomyolysis is characterized by muscle necrosis which causes the release of myoglobin into the bloodstream.</li>
<li>
Clinical manifestations can range from asymptomatic elevation of CPK to life-threatening cases with extremely high CPK levels, electrolyte imbalance, and acute renal failure.</li>
<li>
Classic triad is: muscle aches and pains, weakness, and tea-colored urine.</li>
<li style="text-align: justify;">
Numerous recreational drugs, pharmaceuticals, and toxins can alter myocyte function. Ethanol, statins, and cocaine in particular have high risk to cause rhabdomyolysis<font face="Roboto, sans-serif"><span style="font-size: 16px;">.</span></font></li>
<li>
50% of cases of statin-induced-rhabdomyolysis were due to drug interactions.</li>
</ul>
<div align='center'>
<a href='http://www.umem.org/educational_pearls/3481/' target='_blank'><b>CLICK TO VIEW MORE IN-DEPTH INFORMATION</b></a><br/>
(Must disable pop-up blocker to open new window)
</div>
<fieldset><legend>References</legend>
<div class="cit" style="font-size: 0.8465em; line-height: 1.45em; font-family: arial, helvetica, clean, sans-serif;">
<span style="font-family: Arial, Verdana, sans-serif; font-size: 12px;">A reappraisal of risks and benfits of treating to target with cholesterol lowering drugs. Alla VM, et al. Drugs. 2913 Jul; 73 (10) :1025-54.</span></div>
<div class="cit" style="font-size: 0.8465em; line-height: 1.45em; font-family: arial, helvetica, clean, sans-serif;">
</div>
<div class="cit" style="font-size: 0.8465em; line-height: 1.45em; font-family: arial, helvetica, clean, sans-serif;">
<span style="color: rgb(33, 33, 33); font-family: Lato, sans-serif; font-size: 15px;">Malignant drug-induced rhabdomyolysis. Gheshlaghi F. J Nephropathology. 2012; 1(1): 59-60.</span></div>
<div class="cit" style="font-size: 0.8465em; line-height: 1.45em; font-family: arial, helvetica, clean, sans-serif;">
</div>
<div class="cit" style="font-size: 0.8465em; line-height: 1.45em; font-family: arial, helvetica, clean, sans-serif;">
<span style="color: rgb(33, 33, 33); font-family: Lato, sans-serif; font-size: 15px;">Nontraumatic drug induced thabdomyolysis: Background,laboratory features, and acute clinical management. </span><span font-size:="" letter-spacing:="" sans="" source="" style="background-color: rgb(252, 252, 252); color: rgb(51, 51, 51); font-family: ">Köppel, C. Med Toxicol Adverse Drug Exp (1989) 4: 108.</span></div>
<div class="auths" style="font-size: 0.923em; font-family: arial, helvetica, clean, sans-serif;">
<h2 nexus="" style="box-sizing: border-box; font-weight: 400; margin-top: 0px; margin-bottom: 0px; line-height: 1.33; font-size: 18px; color: rgb(80, 80, 80); font-family: ">
</h2>
</div>
<p>
</p>
</fieldset>